The world’s 1st commercial human iPSC-derived cardiomyocytes (launched in April 2009)

Cardiotoxicity is one of the major causes of drug attrition from the market and clinical development. Aiming to make it possible to predict toxicity of the compounds at earlier stages in drug development, ReproCELL has started to offer QTempo service in 2008, an in vitro safety pharmacology assay service using the beating cardiomyocytes derived from ES or iPS cells. As the world’s first commercial provider of human iPS cell-derived cardiomyocytes (cells sold in the market since 2009), ReproCELL will continue to lead the field of stem cell application in the drug development processes. ReproCELL’s cardiomyocyte products and services can be flexibly tailored for the customers’ needs by genetic manipulation, making patient-derived cardiomyocytes or any other collaborations.

 

Product List

Human iPS cell-derived cardiomyocytes

• ReproCardio 2 (frozen single cells)
  (New Product)
  Frozen cardiomyocytes which can be used as single cells, cell monolayers and cell clumps depending on your purpose. The necessary reagents are included.
  
• ReproCardio (fresh cell clumps)
  Fresh beating cardiomyocyte clusters which are ready for assay just after delivery. The necessary reagents are included.

Reagents for human iPS cell-derived cardiomyocytes

• ReproCardio culture medium 2 (80mL)
  The medium for maintaining iPS cell-derived cardiomyocytes.
  
• ReproCardio assay medium (100mL)
  Assay medium specially developed for electrophysiological and optical recordings from cardiomyocytes.

Assay service with human iPS cell-derived cardiomyocytes

• QTempo
  Assay service of cardiotoxicity and comprehensive analysis of cardiac ion channels using human iPS cell-derived beating cardiomyocyte clusters